What Is Molecular Diagnostics? The Complete Guide for Clinicians and Lab Scientists

Traditional diagnostic methods—histology, serology, culture—detect disease at the level of morphology, protein expression, or organism growth. Molecular diagnostics operates at a fundamentally different level: it detects and characterises disease by directly analysing nucleic acids (DNA and RNA) and proteins at the molecular scale. This allows diagnosis before symptoms appear, identification of resistance mechanisms that alter treatment, and population-level genomic surveillance. If your laboratory is evaluating whether to adopt or expand molecular diagnostic capabilities, this guide maps the complete technical and clinical landscape.

The term "molecular diagnostics" encompasses a broad range of laboratory techniques that detect specific sequences, structural rearrangements, copy number variations, and expression changes in biological material. As of 2024, the global moleculardiagnostics market was valued at over USD 18 billion, driven by oncology, infectious disease testing, and inherited disorder screening. In India, the sector is expanding rapidly as NABL-accredited laboratories integrate next-generation sequencing (NGS) and multiplex PCR alongside established cytogenetics workflows.

Core Techniques in Molecular Diagnostics

1. Polymerase Chain Reaction (PCR) and Its Variants

PCR amplifies a specific DNA or cDNA sequence exponentially, enabling detection from as few as a single copy of a target. Key variants:

2. Fluorescence In Situ Hybridisation (FISH)

FISH uses fluorescently labelled DNA probes that hybridise to complementary sequences on chromosomes or in tissue sections. The technique visualises gene amplifications, deletions, and translocations directly on morphologically intact cells—a critical advantage over purely molecular methods that destroy cellular architecture. In clinical oncology, FISH is the gold-standard companion diagnostic for HER2 testing, BCR-ABL confirmation, and ALK rearrangement detection.

3. Multiplex Ligation-Dependent Probe Amplification (MLPA)

MLPA is a hybridisation-based technique that simultaneously quantifies up to 50 different genomic sequences in a single PCR-based reaction. It excels at detecting copy number variations (CNVs) in genetic disorders:

•       BRCA1/2 exon deletions in hereditary breast/ovarian cancer

•       SMN1/2 copy number in spinal muscular atrophy (SMA)

•       Duchenne muscular dystrophy exon deletions

•       Chromosomal aneuploidy confirmation in prenatal diagnosis

For laboratories establishing CNV analysis workflows, validated MLPA kits and reagents are a cost-effective, technically accessible entry point that does not require the capital investment of NGS platforms.

4. Next-Generation Sequencing (NGS)

NGS platforms perform massively parallel sequencing of millions of DNA fragments simultaneously, generating gigabases of sequence data per run. Clinical NGS applications include:

•       Tumour mutational burden (TMB) and microsatellite instability (MSI) quantification for immunotherapy eligibility

•       Comprehensive somatic mutation profiling (e.g. FoundationOne CDx, 324-gene panel)

•       Liquid biopsy analysis of circulating tumour DNA (ctDNA) for treatment monitoring

•       Pharmacogenomics (CYP2D6, CYP2C19 for drug metabolism stratification)

•       Constitutional variant analysis for rare genetic disease diagnosis

5. Chromosomal Microarray Analysis (CMA)

CMA uses hybridisation to arrays of oligonucleotide probes to detect chromosomal copy number changes at kilobase resolution—several orders of magnitude more sensitive than conventional G-banding karyotyping. It is now recommended as a first-tier investigation for autism spectrum disorder, intellectual disability, and multiple congenital anomalies.

Clinical Applications of Molecular Diagnostics

Oncology

Molecular diagnostics has redefined cancer treatment through companion diagnostics: biomarker tests that determine eligibility for targeted therapies. The EGFR mutation test for EGFR-TKI eligibility, the PD-L1 immunohistochemistry score for checkpoint inhibitor use, and ALK FISH for crizotinib/alectinib prescribing are all examples of molecular tests that directly gate treatment decisions. Liquid biopsy using circulating tumour DNA now enables treatment monitoring without serial tissue biopsies.

Infectious Disease

Multiplex PCR panels (e.g. BioFire FilmArray) can simultaneously detect 20+ respiratory pathogens from a single nasopharyngeal swab in under 90 minutes—compared to 48–72 hours for culture. Molecular methods also enable resistance genotyping (rifampicin resistance in Mycobacterium tuberculosis via Xpert MTB/RIF) that culture cannot provide within a clinically actionable timeframe.

Inherited Genetic Disorders

Carrier screening, prenatal diagnosis (cell-free fetal DNA from maternal plasma), and newborn expanded screening all rely on molecular diagnostic techniques. MLPA and chromosomal microarray have largely replaced conventional karyotyping for postnatal diagnosis of chromosomal structural abnormalities, offering higher resolution with faster turnaround times.

Transplantation Medicine

HLA typing by sequence-based typing (SBT) or NGS is mandatory for allogeneic stem cell and solid organ transplantation matching. Chimerism analysis post-transplant using short tandem repeat (STR) PCR monitors engraftment and detects early relapse.

Building a Molecular Diagnostics Laboratory: Infrastructure Requirements

For laboratories establishing or upgrading their cytogenetics and FISH-based molecular diagnostics capability, the range of spectral karyotyping and cytogenetics instruments available through DSS Image provides a validated, locally supported starting point for Indian institutions.

For a globally recognised reference framework on implementing molecular diagnostics quality systems, the ISO15189:2022 standard published by ISO defines the accreditation requirements for medical laboratory competence and is the basis for NABL accreditation in India.

Quality Assurance in Molecular Diagnostics

The analytical sensitivity of molecular methods—the ability to detect one mutant allele in ten thousand wild-type alleles—means that contamination control is existentially important. A false-positive PCR result caused by amplicon carryover can incorrectly assign a resistance mutation or indicate a malignancy where none exists. Key quality controls include:

•       No-template controls (NTCs) in every PCR run

•       Positive controls at the assay's lower limit of detection

•       Internal amplification controls to detect inhibition

•       Proficiency testing participation (EQAS)

•       Bidirectional sequencing for all clinically significant variants

•       Independent confirmation of novel or rare variants before clinical reporting

Conclusion

Molecular diagnostics is not a single technology but an integrated ecosystem of nucleic acid analysis methods—each with specific performance characteristics, infrastructure requirements, and clinical indications. PCR remains the workhorse for targeted, time-sensitive testing; FISH provides morphologically contextualised chromosomal analysis; MLPA offers accessible CNV analysis; and NGS delivers comprehensive genomic profiling. The laboratories that derive maximum clinical and operational value from molecular diagnostics are those that deliberately match technique to clinical question, rather than implementing every technology available.

FAQ's

What is the difference between molecular diagnostics and clinical diagnostics?

Clinical diagnostics is the broad category encompassing biochemistry, haematology, immunology, microbiology, histopathology, and molecular methods. Molecular diagnostics is a sub-discipline that specifically analyses nucleic acids and molecular biomarkers rather than analytes like enzymes, antibodies, or cellular morphology.

What samples can be used for molecular diagnostics?

Blood (EDTA, serum, plasma), tissue (fresh, frozen, FFPE), bone marrow, cerebrospinal fluid, urine, buccal swabs, sputum, bronchoalveolar lavage, and saliva. For FISH-based cytogenetics, fixed cell suspensions and FFPE tissue sections are the primary substrates.

Is NGS replacing PCR in molecular diagnostics?

Not entirely. NGS provides comprehensive genomic information but has longer turnaround times, higher reagent costs, and greater bioinformatics requirements. PCR remains the preferred method for targeted single-analyte testing (e.g. single pathogen detection, specific mutation confirmation), while NGS is preferred for broad discovery-mode profiling. Most clinical laboratories use both in a complementary workflow.